MFAP2 and hepatocellular carcinoma: To date, MFAP2 has not been evaluated in breast cancer; however, studies in gastric cancer and hepatocellular carcinomas demonstrate that it has elevated expression associated with poor outcomes (Sun et al., 2020; Zhu et al., 2020).